| [1] |
THOMAS DL. Global elimination of chronic hepatitis[J]. N Engl J Med, 2019, 380(21): 2041-2050. DOI: 10.1056/NEJMra1810477 |
| [2] |
SARIN SK, KUMAR M, ESLAM M, et al. Liver diseases in the Asia-Pacific region: A lancet gastroenterology & hepatology commission[J]. Lancet Gastroenterol Hepatol, 2020, 5(2): 167-228. DOI: 10.1016/S2468-1253(19)30342-5 |
| [3] |
ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904. DOI: 10.1016/j.jhep.2018.05.036 |
| [4] |
SEKI E, BRENNER DA. Recent advancement of molecular mechanisms of liver fibrosis[J]. J Hepatobiliary Pancreat Sci, 2015, 22(7): 512-518. DOI: 10.1002/jhbp.245 |
| [5] |
DOHI O, YASUI K, GEN Y, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma[J]. Int J Oncol, 2013, 42(2): 411-418. DOI: 10.3892/ijo.2012.1724 |
| [6] |
SHANG J, ZHENG Y, GUO X, et al. Hepatitis B virus replication and sex-determining region Y box 4 production are tightly controlled by a novel positive feedback mechanism[J]. Sci Rep, 2015, 5: 10066. DOI: 10.1038/srep10066 |
| [7] |
HAN S, TANG Q, LU X, et al. Dysregulation of hepatic microRNA expression profiles with Clonorchis sinensis infection[J]. BMC Infect Dis, 2016, 16(1): 724. DOI: 10.1186/s12879-016-2058-1 |
| [8] |
CHEN C, WU CQ, ZHANG ZQ, et al. Loss of expression of miR-335 is implicated in hepatic stellate cell migration and activation[J]. Exp Cell Res, 2011, 317(12): 1714-1725. DOI: 10.1016/j.yexcr.2011.05.001 |
| [9] |
LIU H, LI W, CHEN C, et al. MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma[J]. Tumour Biol, 2015, 36(8): 6313-6319. DOI: 10.1007/s13277-015-3317-2 |
| [10] |
YIN C. Molecular mechanisms of Sox transcription factors during the development of liver, bile duct, and pancreas[J]. Semin Cell Dev Biol, 2017, 63: 68-78. DOI: 10.1016/j.semcdb.2016.08.015 |
| [11] |
JIAO Y, ZHAO J, ZHANG Z, et al. SRY-Box containing gene 4 promotes liver steatosis by upregulation of SREBP-1c[J]. Diabetes, 2018, 67(11): 2227-2238. DOI: 10.2337/db18-0184 |
| [12] |
NAKANISHI N, NAKAGAWA Y, TOKUSHIGE N, et al. The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice[J]. Biochem Biophys Res Commun, 2009, 385(4): 492-496. DOI: 10.1016/j.bbrc.2009.05.058 |
| [13] |
OISHI Y, SPANN NJ, LINK VM, et al. SREBP1 contributes to resolution of pro-inflammatory TLR4 signaling by reprogramming fatty acid metabolism[J]. Cell Metab, 2017, 25(2): 412-427. DOI: 10.1016/j.cmet.2016.11.009 |
| [14] |
WANG X, MAO W, FANG C, et al. Dusp14 protects against hepatic ischaemia-reperfusion injury via Tak1 suppression[J]. J Hepatol, 2018, 68(1): 118-129. DOI: 10.1016/j.jhep.2017.08.032 |
| [15] |
HU J, ZHU XH, ZHANG XJ, et al. Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury[J]. J Hepatol, 2016, 64(1): 146-159. DOI: 10.1016/j.jhep.2015.08.021 |
| [16] |
WANG PX, ZHANG XJ, LUO P, et al. Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling[J]. Nat Commun, 2016, 7: 10592. DOI: 10.1038/ncomms10592 |
| [17] |
BAO CX, ZHANG DX, WANG NN, et al. MicroRNA-335-5p suppresses lower extremity deep venous thrombosis by targeted inhibition of PAI-1 via the TLR4 signalingpathway[J]. J Cell Biochem, 2018, 119(6): 4692-4710. DOI: 10.1002/jcb.26647 |
| [18] |
LIU FJ, KAUR P, KAROLINA DS, et al. MiR-335 regulates Hif-1α to reduce cell death in both mouse cell line and rat ischemic models[J]. PLoS One, 2015, 10(6): e0128432. DOI: 10.1371/journal.pone.0128432 |
| [19] |
KABIR TD, LEIGH RJ, TASENA H, et al. A miR-335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts[J]. Aging (Albany NY), 2016, 8(8): 1608-1635. DOI: 10.18632/aging.100987 |
| [20] |
HU Y, HU D, YU H, et al. Hypoxia-inducible factor 1α and ROCK1 regulate proliferation and collagen synthesis in hepatic stellate cells under hypoxia[J]. Mol Med Rep, 2018, 18(4): 3997-4003. http://www.ncbi.nlm.nih.gov/pubmed/30132575 |
| [21] |
ZHANG F, HAO M, JIN H, et al. Canonical hedgehog signalling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis[J]. Br J Pharmacol, 2017, 174(5): 409-423. DOI: 10.1111/bph.13701 |
| [22] |
HAN J, HE Y, ZHAO H, et al. Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway[J]. J Cell Biochem, 2019, 120(9): 14735-14744. DOI: 10.1002/jcb.28734 |
| [23] |
WEI S, ZHOU H, WANG Q, et al. RIP3 deficiency alleviates liver fibrosis by inhibiting ROCK1-TLR4-NF-κB pathway in macrophages[J]. FASEB J, 2019, 33(10): 11180-11193. DOI: 10.1096/fj.201900752R |
| [24] |
SHI CY, FAN Y, LIU B, et al. HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression[J]. Cell Physiol Biochem, 2013, 32(3): 561-568. DOI: 10.1159/000354460 |
| [25] |
KATCHMAN BA, ANTWI K, HOSTETTER G, et al. Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases[J]. Mol Cancer Res, 2011, 9(12): 1621-1631. DOI: 10.1158/1541-7786.MCR-11-0018 |
| [26] |
YANG JW, HIEN TT, LIM SC, et al. Pin1 induction in the fibrotic liver and its roles in TGF-β1 expression and Smad2/3 phosphorylation[J]. J Hepatol, 2014, 60(6): 1235-1241. DOI: 10.1016/j.jhep.2014.02.004 |
| [27] |
|
| [28] |
WANG J, WANG X, LIU F, et al. microRNA-335 inhibits colorectal cancer HCT116 cells growth and epithelial-mesenchymal transition (EMT) process by targeting Twist1[J]. Pharmazie, 2017, 72(8): 475-481. http://www.ncbi.nlm.nih.gov/pubmed/29441907 |
| [29] |
YEO SY, LEE KW, SHIN D, et al. A positive feedback loop bi-stably activates fibroblasts[J]. Nat Commun, 2018, 9(1): 3016. DOI: 10.1038/s41467-018-05274-6 |
| [30] |
LI Z, CHEN B, DONG W, et al. MKL1 promotes endothelial-to-mesenchymal transition and liver fibrosis by activating TWIST1 transcription[J]. Cell Death Dis, 2019, 10(12): 899. DOI: 10.1038/s41419-019-2101-4 |
| [31] |
REN J, ZHANG J, RUDEMILLER NP, et al. Twist1 in infiltrating macrophages attenuates kidney fibrosis via matrix metallopeptidase 13-mediated matrix degradation[J]. J Am Soc Nephrol, 2019, 30(9): 1674-1685. DOI: 10.1681/ASN.2018121253 |
| [32] |
CHEN S, XIA X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met[J]. J Cell Physiol, 2019.[Epub ahead of print]
|
| [33] |
BOUATTOUR M, RAYMOND E, QIN S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma[J]. Hepatology, 2018, 67(3): 1132-1149. DOI: 10.1002/hep.29496 |
| [34] |
HU J, CHE L, LI L, et al. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice[J]. Sci Rep, 2016, 6: 20484. DOI: 10.1038/srep20484 |
| [35] |
YOU H, DING W, DANG H, et al. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma[J]. Hepatology, 2011, 54(3): 879-889. DOI: 10.1002/hep.24450 |
| [36] |
YOO BK, GREDLER R, CHEN D, et al. c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF[J]. J Hepatol, 2011, 55(6): 1317-1324. DOI: 10.1016/j.jhep.2011.02.036 |
| [37] |
LI L, PILO GM, LI X, et al. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans[J]. J Hepatol, 2016, 64(2): 333-341. DOI: 10.1016/j.jhep.2015.10.004 |
| [38] |
WANG RK, SHAO XM, YANG JP, et al. MicroRNA-145 inhibits proliferation and promotes apoptosis of HepG2 cells by targeting ROCK1 through the ROCK1/NF-κB signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(7): 2777-2785. http://www.ncbi.nlm.nih.gov/pubmed/31002128 |
| [39] |
WANG Y, ZENG XD, WANG NN, et al. Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma[J]. Mol Cancer, 2018, 17(1): 89. DOI: 10.1186/s12943-018-0837-6 |
| [40] |
LIANG H, ZHANG C, GUAN H, et al. LncRNA DANCR promotes cervical cancer progression by upregulating ROCK1 via sponging miR-335-5p[J]. J Cell Physiol, 2019, 234(5): 7266-7278. DOI: 10.1002/jcp.27484 |
| [41] |
GUO D, LI Y, CHEN Y, et al. DANCR promotes HCC progression and regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1 pathway[J]. Cell Prolif, 2019, 52(4): e12628.
|
| [42] |
MENG J, CHEN S, HAN JX, et al. Twist1 regulates vimentin through Cul2 circular RNA to promote EMT in hepatocellular carcinoma[J]. Cancer Res, 2018, 78(15): 4150-4162. DOI: 10.1158/0008-5472.CAN-17-3009 |
| [43] |
XIAO T, ZHANG Q, ZONG S, et al. Protease-activated receptor-1 (PAR1) promotes epithelial-endothelial transition through Twist1 in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 185. DOI: 10.1186/s13046-018-0858-4 |
| [44] |
YIN J, WANG L, ZHU JM, et al. Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway[J]. Oncotarget, 2016, 7(16): 21939-21951. DOI: 10.18632/oncotarget.7877 |
| [45] |
YALIM-CAMCI I, BALCIK-ERCIN P, CETIN M, et al. ETS1 is coexpressed with ZEB2 and mediates ZEB2-induced epithelial-mesenchymal transition in human tumors[J]. Mol Carcinog, 2019, 58(6): 1068-1081. DOI: 10.1002/mc.22994 |
| [46] |
|
| [47] |
WANG F, LI L, PIONTEK K, et al. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma[J]. Hepatology, 2018, 67(3): 940-954. DOI: 10.1002/hep.29586 |
| [48] |
DU WW, TANG HC, LEI Z, et al. miR-335-5p inhibits TGF-beta1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1[J]. Respir Res, 2019, 20(1): 225. DOI: 10.1186/s12931-019-1184-x |
| [49] |
SUN ZF, ZHANG Z, LIU ZD, et al. MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2[J]. Med Oncol, 2014, 31(6): 982. DOI: 10.1007/s12032-014-0982-8 |
DownLoad:
